Reported Sunday, Tourmaline Bio Presents TRANQUILITY Phase 2 Data Showing Pacibekitug Achieves Consistent hs-CRP Reductions Across Clinically Meaningful Subgroups

Benzinga · 09/02/2025 07:40

Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups 

Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity, including lipoprotein(a), fibrinogen, and serum amyloid A